ArticleCureus2026
Acute Pazopanib-Associated Interstitial Lung Disease in a Patient With Ulcerative Colitis and Metastatic Sarcoma: A Case Report.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pazopanib is used in the treatment of advanced renal cell carcinoma and soft tissue sarcoma. While pneumothorax is a recognized pulmonary complication, interstitial lung disease (ILD) typically occurs after months of therapy. We present a rare case of acute onset ILD occurring within 72 hours of initiating pazopanib in a 43-year-old male with metastatic sarcoma and a history of ulcerative colitis. The patient developed rapidly progressive hypoxemic respiratory failure shortly after starting pazopanib. Extensive infectious and autoimmune workups were negative. Imaging findings, combined with a favorable clinical response to corticosteroids, supported the diagnosis of drug-induced ILD (DILD). The clinical course was further complicated by a persistent right-sided pneumothorax and ultimately fatal respiratory failure. This case highlights the potential for acute pazopanib-associated ILD, particularly in patients with predisposing risk factors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.